Opioid-Free Total Shoulder With Suzetrigine
Opioid-Free Postoperative Analgesia With Suzetrigine Following Total Shoulder Arthroplasty: A Prospective Randomized Controlled Noninferiority Trial
This prospective, randomized, unblinded, controlled noninferiority study may benefit patients by determining whether an opioid-free postoperative analgesic pathway utilizing suzetrigine can provide adequate pain control following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing pathway. If effective, this strategy may reduce or eliminate routine postoperative opioid use and associated adverse effects while maintaining patient satisfaction and adequate pain control. More broadly, this study will provide prospective data regarding the effectiveness and safety of suzetrigine following total shoulder arthroplasty and may help inform future opioid-free postoperative pain management protocols.
調査の概要
詳細な説明
Objective 1: To determine whether an opioid-free postoperative analgesic pathway utilizing suzetrigine provides noninferior postoperative pain control at 24 hours following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing postoperative analgesic pathway.
Hypothesis 1: Postoperative pain at 24 hours among patients randomized to the opioid-free suzetrigine pathway will be noninferior to postoperative pain among patients randomized to the standard opioid-containing pathway.
Objective 2: To compare postoperative opioid consumption, requirement for rescue opioid analgesia, time to first rescue opioid, postoperative pain scores, opioid-related adverse effects, and patient satisfaction between treatment groups.
Hypothesis 2: Patients randomized to the opioid-free suzetrigine pathway will have lower cumulative postoperative opioid consumption and reduced need for rescue opioid analgesia without clinically meaningful worsening of postoperative pain, or patient satisfaction.
Objective 3: To evaluate the safety profile of suzetrigine following total shoulder arthroplasty by characterizing adverse events, medication-related adverse effects, drug-drug interactions, treatment discontinuation, emergency department visits, unplanned readmissions, and reoperations.
Hypothesis 3: Patients randomized to the opioid-free suzetrigine pathway will have lower rates of opioid-related adverse events, including sedation, respiratory depression, nausea, and constipation, compared with patients randomized to the standard opioid-containing pathway.
Objective 4: To evaluate shoulder-specific functional outcomes and determine whether preoperative patient resilience is associated with postoperative pain control, opioid requirements, rescue opioid use, and patient satisfaction.
Hypothesis 4: Shoulder-specific patient-reported outcomes will be comparable between treatment groups. Greater preoperative resilience, as measured by the CD-RISC-10, will be associated with lower postoperative pain, reduced opioid consumption, decreased need for rescue opioid analgesia, and greater satisfaction with pain control.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Caleb J Michalek, BS
- 電話番号:704-323-3698
- メール:caleb.michalek@orthocarolina.com
研究連絡先のバックアップ
- 名前:Caleb Lifsey
- 電話番号:704-323-2412
- メール:caleb.lifsey@orthocarolina.com
研究場所
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28207
- OrthoCarolina Research Institute
-
主任研究者:
- Nady Hamid, MD
-
コンタクト:
- Caleb J Michalek, BS
- 電話番号:704-323-3698
- メール:caleb.michalek@orthocarolina.com
-
コンタクト:
- Caleb Lifsey
- 電話番号:704-323-2412
- メール:caleb.lifsey@orthocarolina.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years
- Undergoing elective primary anatomic or reverse total shoulder arthroplasty
- English-speaking (for patient-reported outcome assessments)
Exclusion Criteria:
-
Revision arthroplasty procedures
-
Total shoulder arthroplasty performed for a fracture-related indication, including acute fractures and chronic fracture sequelae (e.g., malunion or nonunion)
-
History of chronic opioid use (defined as daily or near-daily use for ≥90 days preoperatively)
-
Contraindications to suzetrigine:
- Known allergy or hypersensitivity to suzetrigine
- Current use of strong CYP3A inhibitors (contraindicated per FDA labeling)
- Current use of strong or moderate CYP3A inducers (should be avoided per FDA labeling)
- Severe hepatic impairment (Child-Pugh Class C)
- Severe renal impairment (eGFR <15 mL/min/1.73 m²)
-
Pregnancy or breastfeeding
-
Inability to complete patient-reported outcome measures
-
Simultaneous bilateral arthroplasty
-
Unable or unwilling to provide informed consent or comply with study procedures
-
Total shoulder arthroplasty performed for an oncologic indication
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Standard Opioid-Containing Pathway
Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups. |
Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days. |
|
実験的:Opioid-Free Suzetrigine Pathway
Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days. |
Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain Numeric Rating Scale (NRS)
時間枠:24 hours post-surgery
|
The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at 24 hours following surgery. |
24 hours post-surgery
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain Numeric Rating Scale (NRS)
時間枠:From enrollment to the end of treatment at 1 year
|
The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) |
From enrollment to the end of treatment at 1 year
|
|
Morphine Milligram Equivalents (MME)
時間枠:24 hours postoperative
|
Cumulative opioid consumption converted to MME |
24 hours postoperative
|
|
Morphine Milligram Equivalents (MME)
時間枠:48 hours postoperative
|
Cumulative opioid consumption converted to MME |
48 hours postoperative
|
|
Rescue opioid analgesia
時間枠:From enrollment to the end of treatment at 1 year
|
Requirement for rescue opioid analgesia (yes/no) |
From enrollment to the end of treatment at 1 year
|
|
Patient satisfaction with overall pain control
時間枠:From enrollment to the end of treatment at 1 year
|
Patient satisfaction with overall pain control, measured on a scale of 0-10 with 0 being less satisfied and 10 being completely satisfied. |
From enrollment to the end of treatment at 1 year
|
|
Hospital length of stay
時間枠:At the time of surgery treatment.
|
Time spent in hospital |
At the time of surgery treatment.
|
|
American Shoulder and Elbow Surgeons (ASES) Shoulder Score
時間枠:From enrollment to the end of treatment at 1 year
|
The American Shoulder and Elbow Surgeons Shoulder Score (ASES) was designed to assess the condition of the shoulder, regardless of disease pathology. The ASES is a composite instrument, requiring both a physician assessment and a patient-completed portion; however, it is commonly presented as solely the patient-reported survey. This includes a section on pain (7 items) and a section on activities of daily living (10 items). Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition. |
From enrollment to the end of treatment at 1 year
|
|
Single Assessment Numeric Evaluation (SANE)
時間枠:From enrollment to the end of treatment at 1 year
|
Patients are asked: "How would you rate your shoulder today as a percentage of normal (0% to 100% scale, with 100% being a completely normal shoulder)?" |
From enrollment to the end of treatment at 1 year
|
|
Simple Shoulder Test (SST)
時間枠:From enrollment to the end of treatment at 1 year
|
Self-reported questionnaire that evaluates shoulder function, comfort, and strength through simple "yes" or "no" questions that result in 0% (worst function) to 100% (best function) score. |
From enrollment to the end of treatment at 1 year
|
協力者と研究者
捜査官
- 主任研究者:Nady Hamid, MD、OrthoCarolina Research Institute, Inc.
出版物と役立つリンク
一般刊行物
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.
- Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013 Apr;33(4):383-91. doi: 10.1002/phar.1223.
- American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012 Feb;116(2):248-73. doi: 10.1097/ALN.0b013e31823c1030. No abstract available.
- Sloan M, Premkumar A, Sheth NP. Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460. doi: 10.2106/JBJS.17.01617.
- Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The Opioid Crisis: a Comprehensive Overview. Curr Pain Headache Rep. 2018 Feb 23;22(3):16. doi: 10.1007/s11916-018-0670-z.
- Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21.
- Wylde V, Beswick A, Bruce J, Blom A, Howells N, Gooberman-Hill R. Chronic pain after total knee arthroplasty. EFORT Open Rev. 2018 Aug 16;3(8):461-470. doi: 10.1302/2058-5241.3.180004. eCollection 2018 Aug.
- Klein B, Faridi A, von Tempelhoff GF, Heilmann L, Mittermayer C, Rath W. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res. 2002 Dec 15;108(5-6):291-6. doi: 10.1016/s0049-3848(03)00094-x.
- Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013 Jan;14(1):49-62. doi: 10.1038/nrn3404. Epub 2012 Dec 12.
- Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S; study investigators. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017 Apr;16(4):291-300. doi: 10.1016/S1474-4422(17)30005-4. Epub 2017 Feb 17.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- SE001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。